Drug Trial Radar · NCT06806592
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
414
Actual
Start
Sep 13, 2025
Primary completion
Apr 15, 2027
Study completion Apr 28, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease. Participants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Interstitial Lung Diseases
- Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions
NerandomilastDrug
Nerandomilast
Placebo matching nerandomilastDrug
Placebo matching nerandomilast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26Time frame: At baseline and at Week 26
Locations
153 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic-Arizona
Scottsdale, Arizona
University of California Los Angeles
Los Angeles, California
Paradigm Clinical Research - San Diego
San Diego, California
National Jewish Health
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Meris Clinical Research-Brandon-69466
Brandon, Florida
Miami VA Healthcare System
Miami, Florida
Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
Atlanta, Georgia
Augusta University
Augusta, Georgia
Northwestern University
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
Northshore University Health System
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic, Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Northwell Health
Great Neck, New York
NYU Langone Health
New York, New York
New York Presbyterian Hospital -Columbia University
New York, New York
Onsite Clinical Solutions
Salisbury, North Carolina
Southeastern Research Center-Winston Salem-69289
Winston-Salem, North Carolina
Temple Lung Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
The University of Texas Health Science Center at Houston
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
University of Utah Health Sciences Center
Salt Lake City, Utah
Rheumatology and Pulmonary Clinic
Beckley, West Virginia
University of Wisconsin
Madison, Wisconsin
Royal Prince Alfred Hospital
Camperdown, Sydney, New South Wales, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Krems University Hospital
Krems, Austria
Klinikum Wels - Grieskirchen GmbH
Wels, Austria
Beijing Chao-Yang Hospital
Beijing, China
China-Japan Friendship Hospital
Beijing, China
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.